 The goal of this study was to determine the effect on overall survival and progression free survival by adding iniparib BSI-201SAR240550 to the combination of gemcitabinecarboplatin in adult patients with triple negative breast cancer estrogen receptor ER-negative, progesterone receptor PR-negative, and human epidermal growth factor receptor 2 HER2-negative. 